Abstract
There are estimated to be more than 400 million people chronically infected with the hepatitis B virus (HBV) worldwide (Fig. 1) (1). At least 20–30% of those chronically infected will die of complications of chronic liver disease including cirrhosis and liver cancer (2,3). The World Health Organization (WHO) places HBV in the top 10 causes of death worldwide (4). The estimated viral burden in the United States is 1.5 million people, with disease concentrated in ethnic subgroups and populations with high-risk behavior, and health care costs to the North American economy that exceed $350 million per year. Although the United States is considered an area of low-prevalence hepatitis B infection, the incidence of new cases, the prevalence of carriers, and the burden of acute and chronic disease maintain hepatitis B high among the important communicable diseases. It is estimated that 300,000 new cases of hepatitis B infection occurred each year in the United States in the 1970s and 1980s. Currently about 125,000 new cases occur each year in North America. These acute infections have led to at least 27,000–42,000 chronic carriers, 17,000 hospitalizations, 300 cases of fulminant liver failure, and ultimately 4000–5500 deaths per year in the United States from cirrhosis and primary liver cancer as well as the morbidity and cost of liver transplantation in approx 350 patients per year (5–11). The age-specific incidence of acute HBV infection is shown in Fig. 2. The risk of developing chronic HBV infection after acute exposure ranges from 1% to 5% for adults and 90% for infants born to infected mothers (Fig. 3). Once chronic infection has occurred, a heterogeneous group of patients or clinical profiles is evident based on a combination of viral replication, fibrosis progression, host immune response, and presence or evolution of viral mutants.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maynard, J. E. (1990) Hepatitis B: global importance and need for control. Vaccine 8(Suppl), S18–S20.
Dodd, R. Y. and Nath, N. (1987) Increased risk for lethal forms of liver disease among HBsAg-positive blood donors in the United States. J. Virol. Methods 17, 81–94.
Lee, W. M. (1997) Hepatitis B virus infection. N. Engl. J. Med. 337, 1733–1745.
Hoofnagle, J. H. (1990) Chronic hepatitis B. N. Engl. J. Med. 323, 337–339.
Moyer, L.A. and Mast, E.E. (1994) Hepatitis B: virology, epidemiology, disease, and prevention, and an overview of viral hepatitis. Am. J. Prev. Med. 10(Suppl), 45–55.
Kane, M. (1995) Epidemiology of hepatitis B infection in North America. Vaccine 13(Suppl 1), S16–S17.
McMahon, B. J., Lanier, A. P., and Wainwright, R. B. (1998) Hepatitis B and hepatocellular carcinoma in Eskimo/Inuit population. Int. J. Circumpolar. Health 57(Suppl 1), 414–419.
Chu, C. M. (2000) Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma. J. Gastroenterol. Hepatol. 15(Suppl), E25–E30.
de Franchis, R., Meucci, G., Vecchi, M., et al. (1993) The natural history of asymptomatic hepatitis B surface antigen carriers. Ann. Intern. Med. 118, 191–194.
Fattovich, G., Brollo, L., Giustina, G., et al. (1991) Natural history and prognostic factors for chronic hepatitis type B. Gut 32, 294–298.
Lok, A. S. (1992) Natural history and control of perinatally acquired hepatitis B virus infection. Dig. Dis. 10, 46–52.
Angus, P.W. (1997) Review: hepatitis B and liver transplantation. J. Gastroenterol. Hepatol. 12, 217–223.
Arevalo, J. A. and Washington, A. E. (1988) Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA 259, 365–369.
Blumberg, B. S. (1977) Australia antigen and the biology of hepatitis B. Science 197, 17–25.
Perrault, J., McGill, D.B., Ott, B.J., and Taylor, W. F. (1978) Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 74, 103–106.
Younossi, Z. M., Teran, J.C., Ganiats, T.G., and Carey, W.D. (1998) Ultrasound-guided liver biopsy for parenchymal liver disease: an economic analysis. Dig. Dis. Sci. 43, 46–50.
Piton, A., Poynard, T., Imbert-Bismut, F., et al. (1998) Factors associated with serum alanine transaminase activity in healthy subjects: consequences for the definition of normal values, for selection of blood donors, and for patients with chronic hepatitis C. MULTIVIRC Group. Hepatology 27, 1213–1219.
Knodell, R. G., Ishak, K.G., Black, W. C., et al. (1981) Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1, 431–435.
Hruska, J.F. and Robinson, W. S. (1977) The proteins of hepatitis B Dane particle cores. J. Med. Virol. 1, 119–131.
Summers, J., O’Connell, A., and Millman, I. (1975) Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc. Natl. Acad. Sci. U.S.A 72, 4597–4601.
Albin, C. and Robinson, W.S. (1980) Protein kinase activity in hepatitis B virus. J. Virol. 34, 297–302.
Nassal, M. (1999) Hepatitis B virus replication: novel roles for virus-host interactions. Intervirology 42, 100–116.
Spandau, D.F. and Lee, C. H. (1988) Trans-activation of viral enhancers by the hepatitis B virus X protein. J. Virol. 62, 427–434.
Twu, J. S. and Robinson, W. S. (1989) Hepatitis B virus X gene can transactivate heterologous viral sequences. Proc. Natl. Acad. Sci. USA 86, 2046–2050.
Twu, J.S., Chu, K., and Robinson, W.S. (1989) Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1. Proc. Natl. Acad. Sci. USA 86, 5168–5172.
Chen, H.S., Kaneko, S., Girones, R., et al. (1993) The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J. Virol. 67, 1218–1226.
Zoulim, F., Saputelli, J., and Seeger, C. (1994) Woodchuck hepatitis virus X protein is required for viral infection in vivo. J. Virol. 68, 2026–2030.
Ganem, D. (1996). Hepadnaviridae and their replication. In: “Virology,” 3rd Ed. (Fields, B.N., Eds.). New York: Lippincott-Raven Publishers, pp. 2703–2737
Raney, A. K., Milich, D.R., Easton, A. J., and McLachlan, A. (1990) Differentiation-specific transcriptional regulation of the hepatitis B virus large surface antigen gene in human hepatoma cell lines. J. Virol. 64, 2360–2368.
Cattaneo, R., Will, H., Hernandez, N., and Schaller, H. (1983) Signals regulating hepatitis B surface antigen transcription. Nature 305, 336–338.
Standring, D.N., Rutter, W.J., Varmus, H.E., and Ganem, D. (1984) Transcription of the hepatitis B surface antigen gene in cultured murine cells initiates within the presurface region. J. Virol. 50, 563–571.
Siddiqui, A., Jameel, S., and Mapoles, J. (1987) Expression of the hepatitis B virus X gene in mammalian cells. Proc. Natl. Acad. Sci. USA 84, 2513–2517.
Shaul, Y., Rutter, W. J., and Laub, O. (1985) A human hepatitis B viral enhancer element. EMBO J. 4, 427–430.
Yee, J. K. (1989) A liver-specific enhancer in the core promoter region of human hepatitis B virus. Science 246, 658–661.
Bock, C., Malek, N.P., Tillmann, H.L., Manns, M.P., and Trautwein, C. (2000) The enhancer I core region contributes to the replication level of hepatitis B virus In vivo and In vitro. J. Virol. 74, 2193–2202.
Tur-Kaspa, R., Burk, R.D., Shaul, Y., and Shafritz, D.A. (1986) Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc. Natl. Acad. Sci. USA 83, 1627–1631.
Tur-Kaspa, R., Shaul, Y., Moore, D. D., et al. (1988) The glucocorticoid receptor recognizes a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 167, 630–633.
Neurath, A. R., Kent, S. B., Parker, K., et al. (1986) Antibodies to a synthetic peptide from the preS 120–145 region of the hepatitis B virus envelope are virus neutralizing. Vaccine 4, 35–37.
Le Seyec, J., Chouteau, P., Cannie, I., Guguen-Guillouzo, C., and Gripon, P. (1999) Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain. J. Virol. 73, 2052–2057.
Jung, M. C., Diepolder, H.M., Spengler, U., et al. (1995) Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J. Virol. 69, 3358–3368.
Chiang, P. W., Jeng, K.S., Hu, C. P., and Chang, C.M. (1992) Characterization of a cis element required for packaging and replication of the human hepatitis B virus. Virology 186, 701–711.
Junker-Niepmann, M., Bartenschlager, R., and Schaller, H. (1990) A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. EMBO J. 9, 3389–3396.
Pollack, J. R. and Ganem, D. (1993) An RNA stem-loop structure directs hepatitis B virus genomic RNA encapsidation. J. Virol. 67, 3254–3263.
Pollack, J.R. and Ganem, D. (1994) Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis. J. Virol. 68, 5579–5587.
Hirsch, R. C., Loeb, D. D., Pollack, J. R., and Ganem, D. (1991) cis-acting sequences required for encapsidation of duck hepatitis B virus pregenomic RNA. J. Virol. 65, 3309–3316.
Bartenschlager, R. and Schaller, H. (1992) Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J. 11, 3413–3420.
Nassal, M. and Schaller, H. (1993) Hepatitis B virus replication. Trends Microbiol. 1, 221–228.
Tavis, J. E., Perri, S., and Ganem, D. (1994) Hepadnavirus reverse transcription initiates within the stem-loop of the RNA packaging signal and employs a novel strand transfer. J. Virol. 68, 3536–3543.
Summers, J. and Mason, W.S. (1982) Replication of the genome of a hepatitis B—like virus by reverse transcription of an RNA intermediate. Cell 29, 403–415.
Oberhaus, S.M. and Newbold, J.E. (1995) Detection of an RNase H activity associated with hepadnaviruses. J. Virol. 69, 5697–5704.
Lien, J. M., Aldrich, C.E., and Mason, W. S. (1986) Evidence that a capped oligoribonu-cleotide is the primer for duck hepatitis B virus plus-strand DNA synthesis. J. Virol. 57, 229–236.
Loeb, D.D., Hirsch, R.C., and Ganem, D. (1991) Sequence-independent RNA cleavages generate the primers for plus strand DNA synthesis in hepatitis B viruses: implications for other reverse transcribing elements. EMBO J. 10, 3533–3540.
Tuttleman, J. S., Pourcel, C., and Summers, J. (1986) Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47, 451–460.
Wu, T.T., Coates, L., Aldrich, C.E., Summers, J., and Mason, W.S. (1990) In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 175, 255–261.
Gauthier, J., Bourne, E. J., Lutz, M.W., et al. (1999) Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J. Infect. Dis. 180, 1757–1762.
Ishak, K. G. (1994) Chronic hepatitis: morphology and nomenclature. Mod. Pathol. 7, 690–713.
Bedossa, P. and Poynard, T. (1996) An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24, 289–293.
Eddleston, A. (1986) Interferons in the treatment of chronic hepatitis B virus infection. Med. Clin. North Am. Suppl, 25–30.
Di Bisceglie, A. M. (1995) Long-term outcome of interferon-alpha therapy for chronic hepatitis B. J. Hepatol. 22, 65–67.
Korenman, J., Baker, B., Waggoner, J., Everhart, J.E., Di Bisceglie, A.M., and Hoofnagle, J. H. (1991) Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann. Intern. Med. 114, 629–634.
Hadziyannis, S. (1995) Hepatitis Be Antigen Negative Chronic Hepatitis B: from Clinical Recognition to Pathogenesis and Treatment. Viral Hepat. Rev. 1, 7–36.
Brunetto, M.R., Oliveri, F., Rocca, G., et al. (1989) Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 10, 198–202.
Hadziyannis, S., Bramou, T., Makris, A., Moussoulis, G., Zignego, L., and Papaioannou, C. (1990) Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J. Hepatol. 11Suppl 1(S133-136).
Santantonio, T., Mazzola, M., Iacovazzi, T., Miglietta, A., Guastadisegni, A., and Pastore, G. (2000) Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J. Hepatol. 32, 300–306.
Dusheiko, G. (1999) Lamivudine therapy for hepatitis B infection. Scand. J. Gastroenterol. 230(Suppl), 76–81.
Dienstag, J.L. (1997) Sexual and perinatal transmission of hepatitis C. Hepatology 26, 66S–70S.
Dienstag, J. L., Schiff, E. R., Mitchell, M., et al. (1999) Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 30, 1082–1087.
Liaw, Y. F., Leung, N.W., Chang, T.T., et al. (2000) Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 119, 172–180.
Hadziyannis, S. J., Papatheodoridis, G. V., Dimou, E., Laras, A., and Papaioannou, C. (2000) Efficacy of long-term Lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32, 847–851.
Fischer, K.P., Gutfreund, K. S., and Tyrrell, D.L. (2001) Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist. Updat. 4, 118–128.
Gutfreund, K. S., Williams, M., George, R., et al. (2000) Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance. J. Hepatol. 33, 469–475.
Kobayashi, S., Ide, T., and Sata, M. (2001) Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers. J. Hepatol. 34, 584–586.
Leung, N. W., Lai, C. L., Chang, T. T., et al. (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33, 1527–1532.
Perrillo, R., Rakela, J., Dienstag, J., et al. (1999) Multicenter study of lamivudine therapy for hepatitis B after liver transplantation.Lamivudine Transplant Group. Hepatology 29, 1581–1586.
De Man, R.A., Heijtink, R.A., Niesters, H.G., and Schalm, S.W. (1995) New developments in antiviral therapy for chronic hepatitis B infection. Scand. J. Gastroenterol. 212(Suppl), 100–104.
Bridges, E.G. and Cheng, Y.C. (1995) Use of novel beta-L(−)-nucleoside analogues for treatment and prevention of chronic hepatitis B virus infection and hepatocellular carcinoma. Prog. Liver Dis. 13, 231–245.
Cossart, Y. E. (1972) Australia antigen and hepatitis in renal units. Proc. Eur. Dial. Transplant. Assoc. 9, 235–242.
Davis, H. L. (1999) DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt. Sinai J. Med. 66, 84–90.
Tiollais, P., Pourcel, C., and Dejean, A. (1985) The hepatitis B virus. Nature 317, 489–495.
Carman, W.F. (1997) The clinical significance of surface antigen variants of hepatitis B virus. J. Viral Hepat. 4(Suppl 1), 11–20.
Yoshida, E. M., Ramji, A., Erb, S.R., et al. (2000) De novo acute hepatitis B infection in a previously vaccinated liver transplant recipient due to a strain of HBV with a Met 133 Thr mutation in the “a” determinant. Liver 20, 411–414.
Ijaz, S., Torre, F., Tedder, R.S., Williams, R., and Naoumov, N.V. (2001). Novel immunoassay for the detection of hepatitis B surface ‘escape’ mutants and its application in liver transplant recipients. J.Med.Virol. 63, 210–216.
Rossner, M. T. (1992). Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J.Med.Virol. 36, 101–117.
Jean-Jean, O., Weimer, T., de Recondo, A. M., Will, H., and Rossignol, J. M. (1989). Internal entry of ribosomes and ribosomal scanning involved in hepatitis B virus P gene expression. J.Virol. 63, 5451–5454.
Lin, C.G. and Lo, S.J. (1992). Evidence for involvement of a ribosomal leaky scanning mechanism in the translation of the hepatitis B virus pol gene from the viral pregenome RNA. Virology 188, 342–352.
Lanford, R.E., Kim, Y.H., Lee, H., Notvall, L., and Beames, B. (1999). Mapping of the hepatitis B virus reverse transcriptase TP and RT domains by transcomplementation for nucleotide priming and by protein-protein interaction. J.Virol. 73, 1885–1893.
Bartenschlager, R. and Schaller, H. (1988). The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription. EMBO J. 7, 4185–4192.
Jacobo-Molina, A., Ding, J., Clark, A.D., Jr., Lu, X., Williams, R.L., Williams, R. L., Kamer, G., Ferria, A.L., and Clark, P. (1993). Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc.Natl.Acad.Sci.U.S.A 90, 6320–6324.
Bartholomeusz, A. and Thompson, P. (1999). Flaviviridae polymerase and RNA replication. J.Viral Hepat. 6, 261–270.
Locarnini, S. and Birch, C. (1999). Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients. J.Hepatol. 30, 536–550.
Stuyver, L.J., Locarnini, S. A., Lok, A., Richman, D. D., Carman, W. F., Dienstag, J.L., and Schinazi, R. F. (2001). Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33, 751–757.
Das, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G., and Arnold, E. (2001). Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J.Virol. 75, 4771–4779.
Hunt, C.M., McGill, J. M., Allen, M. I., and Condreay, L.D. (2000). Clinical relevance of hepatitis B viral mutations. Hepatology 31, 1037–1044.
Lok, A. S., Akarca, U., and Greene, S. (1994). Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc.Natl.Acad.Sci.U.S.A 91, 4077–4081.
Gunther, S., Fischer, L., Pult, I., Sterneck, M., and Will, H. (1999). Naturally occurring variants of hepatitis B virus. Adv.Virus Res. 52, 125–137.
Cabrerizo, M., Bartolome, J., Ruiz-Moreno, M., Otero, M., Lopez-Alcorocho, J.M., and Carreno, V. (1996). Distribution of the predominant hepatitis B virus precore variants in hepatitis B e antigen-positive children and their effect on treatment response. Pediatr.Res. 39, 980–984.
Lampertico, P., Manzin, A., Rumi, M.G., Paolucci, S., Del Ninno, E., Clementi, M., and Colombo, M. (1995). Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon. J.Viral Hepat. 2, 251–256.
Lopez-Alcorocho, J. M., Cabrerizo, M., Bartolome, J., Cotonat, T., and Carreno, V. (1995). Analysis of hepatitis B virus precore variants in hepatitis B e antibody-positive patients treated with prednisone plus interferon. J.Viral Hepat. 2, 279–284.
Alberti, A., Pontisso, P., Chemello, L., Fattovich, G., Benvegnu, L., Belussi, F., and De Mitri, M. S. (1995). The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J.Hepatol. 22, 38–41.
Benhamou, Y., Bochet, M., Thibault, V., Di, M., V, Caumes, E., Bricaire, F., Opolon, P., Katlama, C., and Poynard, T. (1999). Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 30, 1302–1306.
Bessesen, M., Ives, D., Condreay, L., Lawrence, S., and Sherman, K.E. (1999) Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin. Infect. Dis. 28, 1032–1035.
Thibault, V., Benhamou, Y., Seguret, C., et al. (1999) Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J. Clin. Microbiol. 37, 3013–3016.
Bonino, F. and Smedile, A. (1986) Delta agent (type D) hepatitis. Semin. Liver Dis. 6, 28–33.
Hadziyannis, S.J. (1983) Delta antigen positive chronic liver disease in Greece: clinical aspects and natural course. Prog. Clin. Biol. Res. 143, 209–217.
Rizzetto, M., Shih, J.W., Gocke, D. J., Purcell, R. H., Verme, G., and Gerin, J.L. (1979) Incidence and significance of antibodies to delta antigen in hepatitis B virus infection. Lancet 2, 986–990.
Rizzetto, M., Purcell, R.H., and Gerin, J. L. (1980) Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet 1, 1215–1218.
Rizzetto, M. (1993) Hepatitis delta virus disease: an overview. Prog. Clin. Biol. Res. 382, 425–430.
Cenac, A., Pedroso, M. L., Djibo, A., et al. (1995) Hepatitis B, C, and D virus infections in patients with chronic hepatitis, cirrhosis, and hepatocellular carcinoma: a comparative study in Niger. Am. J. Trop. Med. Hyg. 52, 293–296.
Mion, F., Boillot, O., Gille, D., Chevallier, P., and Paliard, P. (1993) Liver transplantation for posthepatic B-delta cirrhosis: prevention of recurrence with high-dose anti-HBs immunoglobulins. Transplant. Proc. 25, 2638–2639.
Alvarez, F. (1996) Therapy for chronic viral hepatitis. Clin. Invest Med. 19, 381–388.
Bortolotti, F., Jara, P., Barbera, C., et al. (2000) Long term effect of alpha interferon in children with chronic hepatitis B [see comments]. Gut 46, 715–718.
Carreno, V., Porres, J. C., Ruiz-Moreno, M., Gutiez, J., and Bartolome, F. J. (1991) [A controlled study of treatment with recombinant interferon alpha of chronic hepatitis due to the B virus in childhood]. Rev. Esp. Enferm. Dig. 79, 24–28.
Castaneda, G.C., Sotto, E. A., and Lopez, S. P. (1990) Antiviral effect of interferon: the interferon in viral hepatitis. Rev. Roum. Virol. 41, 171–179.
Jara, P. and Bortolotti, F. (1999) Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children. J. Pediatr. Gastroenterol. Nutr. 29, 163–170.
(1996) Hepatitis B immunization/prophylaxis: recommendations for adults/older adults. Nurse Pract. 21, 64,67–64,70.
Mahon, M. M. and James, O.F. (1994) Liver disease in the elderly. J. Clin. Gastroenterol. 18, 330–334.
Malaguarnera, M., Restuccia, S., Ferlito, L., Mazzoleni, G., Giugno, I., and Pistone, G. (2001) Antiviral drugs in chronic hepatitis B: review and meta-analysis. Int. J. Clin. Pharmacol. Ther. 39, 4–11.
Chiaramonte, M., Floreani, A., and Naccarato, R. (1987) Hepatitis B virus (HBV) in the elderly: an underestimated problem? Biomed. Pharmacother. 41, 121–123.
Dienstag, J.L., Perrillo, R.P., Schiff, E.R., Bartholomew, M., Vicary, C., and Rubin, M. (1995) A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333, 1657–1661.
Lai, C.L., Ching, C. K., Tung, A.K., et al. (1997) Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 25, 241–244.
Nevens, F., Main, J., Honkoop, P., et al. (1997) Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 113, 1258–1263.
Honkoop, P., De Man, R. A., Niesters, H.G., et al. (1998). Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J. Viral Hepat. 5, 307–312.
Xiong, X., Flores, C., Yang, H., Toole, J.J., and Gibbs, C. S. (1998) Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28, 1669–1673.
Xiong, X., Yang, H., Westland, C. E., Zou, R., and Gibbs, C.S. (2000) In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance. Hepatology 31, 219–224.
Perrillo, R., Schiff, E., Yoshida, E., et al. (2000) Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 32, 129–134.
Peters, M.G., Singer, G., Howard, T., et al. (1999) Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin. Transplantation 68, 1912–1914.
Brechot, C., Nalpas, B., and Feitelson, M.A. (1996) Interactions between alcohol and hepatitis viruses in the liver. Clin. Lab. Med. 16, 273–287.
Abou-Saif, A. and Lewis, J. H. (2000) Gastrointestinal and hepatic disorders in end-stage renal disease and renal transplant recipients [In Process Citation]. Adv. Ren. Replace. Ther. 7, 220–230.
Samuel, D., Zignego, A.L., Reynes, M., et al. (1995) Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis. Hepatology 21, 333–339.
Gish, R.G., Lau, J. Y., Brooks, L., et al. (1996) Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients. Hepatology 23, 1–7.
Al, F.K., Yoshida, E. M., Davis, J. E., Vartanian, R.K., Anderson, F. H., and Steinbrecher, U. P. (1997) Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine. Transplantation 64, 926–928.
Andreone, P., Caraceni, P., Grazi, G.L., et al. (1998) Lamivudine treatment for acute hepatitis B after liver transplantation. J. Hepatol. 29, 985–989.
Ben-Ari, Z., Shmueli, D., Mor, E., et al. (1997) Beneficial effect of lamivudine pre-and post-liver transplantation for hepatitis B infection. Transplant. Proc. 29, 2687–2688.
Ben-Ari, Z., Shmueli, D., Mor, E., Shapira, Z., and Tur-Kaspa, R. (1997) Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 63, 393–396.
Ben Ari, Z., Zemel, R., Kazetsker, A., Fraser, G., and Tur-Kaspa, R. (1999) Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation. Am. J. Gastroenterol. 94, 663–667.
De Man, R.A., Bartholomeusz, A. I., Niesters, H. G., Zondervan, P.E., and Locarnini, S. A. (1998) The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J. Hepatol. 29, 669–675.
Dodson, S.F., Bonham, C.A., Geller, D. A., Cacciarelli, T.V., Rakela, J., and Fung, J.J. (1999) Prevention of de novo hepatitis B infection in recipients of hepatic allografts from anti-HBc positive donors. Transplantation 68, 1058–1061.
Dodson, S. F. (2000) Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors. Clin. Transplant. 14(Suppl 2), 20–24.
Grellier, L., Mutimer, D., Ahmed, M., et al. (1996) Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 348, 1212–1215.
Gugenheim, J., Baldini, E., Ouzan, D., Sowka, P., and Mouiel, J. (1999) Good results of lamivudine in hepatitis B surface antigen-positive patients with active viral replication before liver transplantation. Transplant. Proc. 31, 554–555.
McCaughan, G. W., Spencer, J., Koorey, D., et al. (1999) Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transplant Surg. 5, 512–519.
Mutimer, D., Dusheiko, G., Barrett, C., et al. (2000) Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up. Transplantation 70, 809–815.
Perrillo, R. P. (1997) Treatment of posttransplantation hepatitis B. Liver Transplant. Surg. 3, S8–12.
Perrillo, R.P., Rakela, J., Dienstag, J., et al. (1999) Multicenter study of lamivudine therapy for hepatitis B after liver transplantation.Lamivudine Transplant Group. Hepatology 29, 1581–1586.
Terrault, N.A., Holland, C. C., Ferrell, L., et al. (1996) Interferon alfa for recurrent hepatitis B infection after liver transplantation. Liver Transplant. Surg. 2, 132–138.
Bartholomew, M.M., Jansen, R. W., Jeffers, L. J., et al. (1997) Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 349, 20–22.
Ling, R., Mutimer, D., Ahmed, M., et al. (1996) Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24, 711–713.
Tipples, G. A., Ma, M. M., Fischer, K.P., Bain, V. G., Kneteman, N.M., and Tyrrell, D. L. (1996) Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivu-dine in vivo. Hepatology 24, 714–717.
Honkoop, P., Niesters, H.G., De Man, R.A., Osterhaus, A.D., and Schalm, S.W. (1997) Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J. Hepatol. 26, 1393–1395.
Chayama, K., Suzuki, Y., Kobayashi, M., et al. (1998) Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 27, 1711–1716.
Liaw, Y. F., Chien, R. N., Yeh, C. T., Tsai, S. L., and Chu, C.M. (1999) Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30, 567–572.
Seta, T., Yokosuka, O., Imazeki, F., Tagawa, M., and Saisho, H. (2000) Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients. J. Med. Virol. 60, 8–16.
Lai, C.L., Chien, R. N., Leung, N. W., et al. (1998) A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 339, 61–68.
Dienstag, J. L., Schiff, E. R., Wright, T. L., et al. (1999) Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341, 1256–1263.
Tassopoulos, N. C., Volpes, R., Pastore, G., et al. (1999) Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Hepatology 29, 889–896.
Wedemeyer, H., Pethig, K., Wagner, D., et al. (1998) Long-term outcome of chronic hepatitis B in heart transplant recipients. Transplantation 66, 1347–1353.
Chen, P. M., Chiou, T.J., Fan, F.S., et al. (1999) Fulminant hepatitis is significantly increased in hepatitis B carriers after allogeneic bone marrow transplantation. Transplantation 67, 1425–1433.
Cooksley, W.G. and McIvor, C.A. (1995) Fibrosing cholestatic hepatitis and HBV after bone marrow transplantation. Biomed. Pharmacother. 49, 117–124.
Fan, F.S., Tzeng, C.H., Yeh, H.M., and Chen, P.M. (1992) Reverse seroconversion of hepatitis B virus infectious status after allogeneic bone marrow transplantation from a carrier donor. Bone Marrow Transplant. 10, 189–191.
Fornairon, S., Pol, S., Legendre, C., et al. (1996) The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 62, 297–299.
Uemoto, S., Inomata, Y., Sannomiya, A., et al. (1998) Posttransplant hepatitis B infection in liver transplantation with hepatitis B core antibody-positive donors. Transplant. Proc. 30, 134–135.
Wachs, M.E., Amend, W. J., Ascher, N. L., et al. (1995) The risk of transmission of hepatitis B from HBsAg(−), HBcAb(+), HBIgM(−) organ donors. Transplantation 59, 230–234.
Fabia, R., Levy, M.F., Crippin, J., et al. (1998) De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact. Liver Transplant. Surg. 4, 119–127.
Lau, G. K., Liang, R., Lee, C. K., et al. (1998) Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core-and anti-hepatitis B surface antibody-positive. J. Infect. Dis. 178, 1585–1591.
Lok, A.S.F. and McMahon, B.J. (2001) Chronic hepatitis B. Hepatology 34, 1225–1241.
Margolis, H. S., Alter, M.J., and Hadler, S. C. (1991) Hepatitis B: evolving epidemiology and implications for control. Semin. Liver Dis. 11, 84–92.
Angus, P., Vaughan, R., Xiong, S., et al. (2003) Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 125, 292–297.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Humana Press Inc.
About this protocol
Cite this protocol
Gish, R.G., Locarnini, S. (2004). Studying the Treatment of Chronic Hepatitis B Viral Infection in Special Populations. In: Hamatake, R.K., Lau, J.Y.N. (eds) Hepatitis B and D Protocols. Methods in Molecular Medicine™, vol 96. Humana Press. https://doi.org/10.1385/1-59259-670-3:465
Download citation
DOI: https://doi.org/10.1385/1-59259-670-3:465
Publisher Name: Humana Press
Print ISBN: 978-1-58829-108-0
Online ISBN: 978-1-59259-670-6
eBook Packages: Springer Protocols